An analysis of 11 studies shows that patients with chronic obstructive pulmonary disease who used inhaled corticosteroids including GlaxoSmithKline's Flovent and AstraZeneca's Pulmicort had a 34% higher risk of developing pneumonia compared with those who did not. Researchers said it remains unclear how the treatments raise the risk and said the finding should not prompt patients to stop taking inhaled steroids.

Full Story:

Related Summaries